Worth reading
44Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
39
¥ million (year-on-year increase in operating loss)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending December 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit¥-237 million operating loss
Net income-250 Millions of yen quarterly net loss
Selling, general and administrative expenses¥237 million
Results for the three months of the current quarterRevenue: 0; cost of sales: 0; gross profit: 0; SG&A expenses: ¥237 million; operating loss: ¥237 million; quarterly net loss: ¥250 million (¥ million)
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing as plannedNew initiatives
Basic agreement with Nikon Cell Innovation toward contract manufacturing of clinical-trial products for KP8011; preparations to open a U.S. research institute; consideration of launching new development pipelines; stepped-up recruitment of R&D personnel; stronger collaboration with business partners; and expanded IR and public-relations functionsKey KPIsA metric the company considers important as a management benchmark.
20 employees (as of 31 March 2026); potential to delay disease progression by 27.9 weeks in the KP2011 clinical trial; clinical-trial phases and progress of each development pipelineMarket Size / Share
ALS market size: ¥825 billion in North America, ¥120 billion in Europe, ¥255 billion in China, ¥25 billion in Japan and ¥100 billion in India. Huntington's disease: ¥315 billion in North America; FTD: ¥30 billion in Japan; hearing loss: ¥6 trillion in Japan; Alzheimer's disease: ¥8 trillion in Japan; subacute spinal cord injury: ¥75 billion; chronic spinal cord injury: ¥2.25 trillion; ischemic stroke: ¥19.5 trillion; chronic traumatic brain injury: ¥825 billion; chronic cerebral hemorrhage: ¥3 trillionNumber of employees
20 employees (10 with Ph.D.s, as of 31 March 2026)| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Operating profit | ¥-237 million (operating loss) |
| Net income | -250 Millions of yen (quarterly net loss) |
| Selling, general and administrative expenses | ¥237 million |
| Results for the three months of the current quarter | Revenue: 0; cost of sales: 0; gross profit: 0; SG&A expenses: ¥237 million; operating loss: ¥237 million; quarterly net loss: ¥250 million (¥ million) |
| Self-assessment against the plan | Progressing as planned |
| Key KPIs | 20 employees (as of 31 March 2026); potential to delay disease progression by 27.9 weeks in the KP2011 clinical trial; clinical-trial phases and progress of each development pipeline |
| Number of employees | 20 employees (10 with Ph.D.s, as of 31 March 2026) |
| Market Size / Share | ALS market size: ¥825 billion in North America, ¥120 billion in Europe, ¥255 billion in China, ¥25 billion in Japan and ¥100 billion in India. Huntington's disease: ¥315 billion in North America; FTD: ¥30 billion in Japan; hearing loss: ¥6 trillion in Japan; Alzheimer's disease: ¥8 trillion in Japan; subacute spinal cord injury: ¥75 billion; chronic spinal cord injury: ¥2.25 trillion; ischemic stroke: ¥19.5 trillion; chronic traumatic brain injury: ¥825 billion; chronic cerebral hemorrhage: ¥3 trillion |
| New initiatives | Basic agreement with Nikon Cell Innovation toward contract manufacturing of clinical-trial products for KP8011; preparations to open a U.S. research institute; consideration of launching new development pipelines; stepped-up recruitment of R&D personnel; stronger collaboration with business partners; and expanded IR and public-relations functions |
Items this document does not state (20)
Net SalesOrdinary incomeGross Profit MarginOperating profit marginFull-year earnings forecastProgress against full-year forecastSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.SG&A expenses increased from ¥198 million in the same period of the previous year to ¥237 million, while research and development expenses were ¥103 million. The decrease in cash and deposits was attributed to spending on R&D, personnel expenses and other working capital requirements.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.